You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK):Aurora A抑制劑JAB-2485臨牀試驗申請獲美國FDA批准
格隆匯 01-17 08:12

格隆匯1月17日丨加科思-B(01167.HK)發佈公吿,公司自主研發的全球首創新藥Aurora A (極光激酶A)抑制劑JAB-2485收到美國食品藥品監督管理局(FDA)新藥臨牀試驗批准通知書(IND),集團將在美國啟動針對多種晚期實體瘤患者的I/IIa期臨牀試驗。

根據披露,JAB-2485是一種高選擇性小分子Aurora A抑制劑,JAB-2485在細胞水平可以抑制Aurora A活性,誘導細胞凋亡,抑制腫瘤生長。目前全球還沒有商業化的同類產品,公司自主研發的JAB-2485是第三家在美國進行臨牀試驗的Aurora A抑制劑。

JAB-2485具有良好的抗腫瘤活性,臨牀前數據表明,JAB-2485在生化和細胞水平上具有高選擇性,Aurora A的抑制活性比對Aurora B的抑制活性高一千多倍,有潛力使小細胞肺癌、三陰乳腺癌等腫瘤患者受益。相關研究表明,Aurora A和SHP2抑制劑有可能是解決KRAS G12C抑制劑耐藥的手段之一,公司同時擁有自主研發的SHP2抑制劑(JAB-3068、JAB-3312)、 Aurora A抑制劑(JAB-2485)和KRAS G12C抑制劑(JAB-21822)三個項目在臨牀試驗階段,日後有望通過展開內部的聯合用藥,為患者帶來更多治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account